(臨床研究) 年長者提升免疫力&抗衰老: TORC1 inhibitor therapy (mTOR)

Drug boosts immune system in elderly people by 40% and it also has antiaging effect in fruit flies brian  wang | July 13, 2018Drugs were created to block a protein called the mammalian target of rapamycin (mTOR) and it boosted the immune system by about 40% in elderly people. They safely reducing infections in elderly volunteers around 40% by enhancing the immune system. In 2004, tests that blocked a similar enzyme in fruit flies gave them a longer lifespan. Science – TORC1 inhibition enhances immune function and reduces infections in the elderly Aging may be regulated by a discrete set of intracellular proteins including the mechanistic target of rapamycin (mTOR) kinase. mTOR functions within two multiprotein complexes called TORC1 and TORC2. Inhibition of TORC1 has extended life span in every species studied to date and ameliorated multiple aging-related pathologies including declining immune function. Mannick et al. now show that low-dose TORC1 inhibitor therapy in elderly humans decreased the incidence of all infections, improved influenza vaccination responses, and up-regulated antiviral immunity. Thus, targeting the TORC1 pathway that regulates aging may have clinical benefits for elderly humans including improvement in immune function and decreased infection rates.

Abstract – TORC1 inhibition enhances immune function and reduces infections in the elderly Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks. A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant (P = 0.001) decrease in the rate of infections reported by elderly subjects for a year after study drug initiation. In addition, we observed an up-regulation of antiviral gene expression and an improvement in the response to influenza vaccination in this treatment group. Thus, selective TORC1 inhibition has the potential to improve immune function and reduce infections in the elderly.